Text Size

Repair of Infected or Contaminated Hernias (RICH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
LifeCell
ClinicalTrials.gov Identifier:
NCT00617357
First received: January 14, 2008
Last updated: November 14, 2011
Last verified: November 2011
History of Changes
  Purpose

This is a prospective, multicenter, interventional, observational, open label, single arm, longitudinal evaluation of ventral incisional hernia repair using LTM in contaminated or infected sites. Three interim analyses are planned to examine the incidence of surgical site events, postoperative resumption of activities and hernia recurrence.


Condition Intervention
Hernia
 Device: LTM (Strattice Reconstructive Tissue Matrix)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Observational Evaluation of Repair of Infected or Contaminated Hernias (RICH) Using LTM

Resource links provided by NLM:

MedlinePlus related topics: Hernia
U.S. FDA Resources

Further study details as provided by LifeCell:

Primary Outcome Measures:
  • Incidence of surgical site events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Resumption of activities of daily living [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 83
Study Start Date: September 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Strattice Reconstructive Tissue Matrix
 Device: LTM (Strattice Reconstructive Tissue Matrix)
Surgical mesh

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • is an adult ≥18 years old.
  • has need of open abdominal incisional repair of a contaminated or infected site
  • has an estimated hernia size of >9cm2 by physical exam

Exclusion Criteria:

  • has a nidus of chronic colonization
  • has a systemic infection at the time of repair.
  • has chronic conditions: hepatic cirrhosis (w/ or w/o ascites); renal failure w/ hemo- or peritoneal dialysis; incomplete resection of malignant disease; or defined collagen disorder.
  • requires chronic immunosuppressive therapy, including steroids or cytotoxic agents.
  • is bedridden or otherwise non-ambulatory.
  • is ASA Class 4 or 5.
  • has a BMI >40.
  • has conditions that would adversely affect subject safety, as per product labeling, including sensitivities to pork or porcine products.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00617357

Locations
United States, California
University of California-San Diego Medical Center
La Jolla, California, United States
United States, Connecticut
Hospital of St Rafael
New Haven, Connecticut, United States
United States, Louisiana
Tulane University Medical Center
New Orleans, Louisiana, United States
Louisiana State University Health Sciences Center
New Orleans, Louisiana, United States, 70121
United States, Maryland
University of Maryland Medical Center
Baltimore, Maryland, United States
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States
United States, Missouri
University of Missouri-Columbia Medical Center
Columbia, Missouri, United States
Washington University
St Louis, Missouri, United States
United States, New York
North Shore University Hospital-Long Island Jewish Health System
Manhasset, New York, United States, 11030
United States, North Carolina
University of North Carolina Hospitals
Chapel Hill, North Carolina, United States
United States, Ohio
University Hospitals of Cleveland
Cleveland, Ohio, United States
United States, Oregon
Oregon Health Sciences University
Portland, Oregon, United States, 97239
United States, Texas
Baylor College of Medicine
Houston, Texas, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
United States, Utah
University of Utah Medical Center
Salt Lake City, Utah, United States
Sponsors and Collaborators
LifeCell
Investigators
Principal Investigator: Kamal Itani, MD Boston VA Healthcare System
  More Information

No publications provided by LifeCell

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: LifeCell
ClinicalTrials.gov Identifier: NCT00617357     History of Changes
Other Study ID Numbers: LFC2007.02.01
Study First Received: January 14, 2008
Last Updated: November 14, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by LifeCell:
incisional hernia
abdominal hernia repair
Ventral incisional hernia repair

Additional relevant MeSH terms:
Hernia
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on May 23, 2013